Phase II trial of dacomitinib in patients with HER2-positive gastric cancer

Conclusions Dacomitinib functions as a single agent in HER2-positive GC patients with a tolerable safety profile. HER2 ECD and sECAD have the potential to be biomarkers for patient selection in a panHER inhibition strategy for HER2-positive GC. (ClinicalTrials.gov: NCT01152853).
Source: Gastric Cancer - Category: Gastroenterology Source Type: research